MDxHealth Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
364
- Stock Symbol
-
MDXH
- Investments
-
5
- Share Price
-
$0.14
- (As of Friday Closing)
MDxHealth General Information
Description
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Contact Information
Website
www.mdxhealth.comCorporate Office
- CAP Business Center
- Rue d'Abhooz, 31, Herstal
- 4040 Liège
- Belgium
Corporate Office
- CAP Business Center
- Rue d'Abhooz, 31, Herstal
- 4040 Liège
- Belgium
MDxHealth Timeline
MDxHealth Stock Performance
As of 13-Nov-2026, MDxHealth’s stock price is $0.14. Its current market cap is $13.7M with 95.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.14 | $0.14 | $0.11 - $4.34 | $13.7M | 95.4M | 6.1M | -$0.73 |
MDxHealth Financials Summary
As of 30-Jun-2026, MDxHealth has a trailing 12-month revenue of $108M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 83,820 | 239,262 | 123,372 | 115,533 |
| Revenue | 108,084 | 107,875 | 90,049 | 70,193 |
| EBITDA | (22,544) | (16,054) | (23,097) | (31,746) |
| Net Income | (37,337) | (33,519) | (38,069) | (43,100) |
| Total Assets | 132,086 | 147,953 | 157,329 | 129,132 |
| Total Debt | 105,846 | 86,604 | 60,064 | 41,265 |
MDxHealth Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MDxHealth Comparisons
Industry
Financing
Details
MDxHealth Competitors (9)
One of MDxHealth’s 9 competitors is Myriad Genetics, a Corporation company based in Salt Lake City, UT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Myriad Genetics | Corporation | Salt Lake City, UT | ||||
| CSI Laboratories | Formerly PE-Backed | Alpharetta, GA | ||||
| Gene By Gene | Formerly VC-backed | Houston, TX | ||||
| DiaCarta | Venture Capital-Backed | Hayward, CA | ||||
| Blueprint Genetics | Formerly VC-backed | Espoo, Finland |
MDxHealth Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MDxHealth Patents
MDxHealth Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3596236-A1 | Mgmt epigenetic deep-sequencing assay | Active | 17-Mar-2017 | ||
| EP-3596236-B1 | Mgmt epigenetic deep-sequencing assay | Active | 17-Mar-2017 | ||
| US-20200010907-A1 | Mgmt epigenetic deep-sequencing assay | Inactive | 17-Mar-2017 | ||
| US-20250215505-A1 | Mgmt epigenetic deep-sequencing assay | Pending | 17-Mar-2017 | ||
| WO-2018167572-A1 | Mgmt epigenetic deep-sequencing assay | Inactive | 17-Mar-2017 | C12Q1/6886 |
MDxHealth Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MDxHealth Investments & Acquisitions (5)
MDxHealth’s most recent deal was a Merger/Acquisition with Exosome Diagnostics for . The deal was made on 15-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Exosome Diagnostics | 15-Sep-2025 | Merger/Acquisition | Diagnostic Equipment | ||
| Exact Sciences (Oncotype DX GPS Prostate Cancer Business) | 07-Mar-2022 | Merger/Acquisition | Diagnostic Equipment | ||
| NovioGendix | 18-Sep-2015 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Signature Diagnostics | 12-Aug-2008 | Later Stage VC | Biotechnology | ||
| Signature Diagnostics | 30-Jan-2008 | Early Stage VC | Biotechnology |
MDxHealth ESG
Risk Overview
Risk Rating
Updated August, 31, 2023
28.42 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,942
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Biotechnology
Subindustry
of 412
Rank
Percentile
MDxHealth Exits (2)
MDxHealth’s most recent exit was on 12-Aug-2008 from Signature Diagnostics. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Signature Diagnostics | 12-Aug-2008 | Completed |
|
||
| Signature Diagnostics | 30-Jan-2008 | Early Stage VC | Completed |
MDxHealth FAQs
-
When was MDxHealth founded?
MDxHealth was founded in 2003.
-
Where is MDxHealth headquartered?
MDxHealth is headquartered in Liège, Belgium.
-
What is the size of MDxHealth?
MDxHealth has 364 total employees.
-
What industry is MDxHealth in?
MDxHealth’s primary industry is Laboratory Services (Healthcare).
-
Is MDxHealth a private or public company?
MDxHealth is a Public company.
-
What is MDxHealth’s stock symbol?
The ticker symbol for MDxHealth is MDXH.
-
What is the current stock price of MDxHealth?
As of 13-Nov-2026 the stock price of MDxHealth is $0.14.
-
What is the current market cap of MDxHealth?
The current market capitalization of MDxHealth is $13.7M.
-
What is MDxHealth’s current revenue?
The trailing twelve month revenue for MDxHealth is $108M.
-
Who are MDxHealth’s competitors?
Myriad Genetics, CSI Laboratories, Gene By Gene, DiaCarta, and Blueprint Genetics are some of the 9 competitors of MDxHealth.
-
What is MDxHealth’s annual earnings per share (EPS)?
MDxHealth’s EPS for 12 months was -$0.73.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
